Using ProteinChip array technology, which is based on the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, we performed proteomic analyses on sera from myelodysplastic syndromes (MDSs) patients with an interstitial deletion of the long arm of chromosome 5 (del(5q)) and those from control individuals. One analysis with 80 samples from 29 patients and 51 control subjects resulted in the detection of 61 peak differences. Another analysis with 36 paired-samples from 18 patients collected before and after the treatment with lenalidomide (Revlimid) identified 19 differential peak features. We also observed differential profiles between the pre-treatment samples from the responders and those from the non-responders reflected by eight peak differences. On the basis of these data we developed two classification models that could distinguish between the diseased and the control subjects or between the responders and the non-responders. Efforts were made to purify and identify a range of differential peak proteins. We conclude that inter-a trypsin inhibitor, heavy chain H4 (fragments), serum transferrin, transthyretin (variants), haemoglobin and a protein peak at m/z 2791 could be potential disease-associated markers for del(5q) MDS. Platelet factor 4 (PF-4) and a peak at m/z 8559 may serve as therapy-associated markers and be potentially useful for monitoring and predicting the response to therapy.
Introduction
Myelodysplastic syndromes (MDSs) are a heterogeneous group of haemopoietic malignancies characterized by ineffective haemopoiesis, blood cytopenia and a hypercellular bone marrow. They may develop at any age and affect approximately 1 in 500 persons over 60 years of age, making them the most common haematological malignancies in this age group. 1, 2 The prognosis for patients with MDS is poor, especially in the elderly. Although various strategies have been used to treat patients with MDS, these diseases are generally considered to be incurable conditions, unless an allogeneic stem cell transplantation can be offered. MDS patients often rely on blood transfusions to manage their symptoms of anaemia and fatigue.
Unfortunately, the transfusions can lead to life-threatening iron overload and toxicity. MDS can eventually lead to acute leukaemia in circa 30À40% patients. 3, 4 For a long time the classification and diagnosis of MDS have been largely carried out on the basis of the morphology, which can be very difficult as bone marrow dysplasia and peripheral cytopenia, the hallmarks of MDS, can be observed under other conditions, such as nutritional deficiency, toxic exposure and infection. [5] [6] [7] In the year 2000, World Health Organization proposed a new scheme integrating morphological, biological, immunophenotypic and genetic characteristics into the classification for MDS. 8 However, there are still difficulties in some cases for a precise classification and subsequently choosing a better treatment scheme on the basis of the current scheme owing to the remarkable haematological, pathological and biological heterogeneity of MDS. Clearly, new markers potentially useful for adding in the classification and monitoring therapy are needed.
Recently, a proteomic approach, known as ProteinChip technology based on the surface-enhanced laser desorption/ ionization time-of-flight mass spectrometry has been demonstrated as a powerful method for cancer diagnosis, as well as biomarker discovery. [9] [10] [11] [12] In this technique, biological fluids or tissue extracts are incubated with various chips for selectively capturing proteins on the basis of the ion exchange, hydrophobic, metal binding or other interactions. The bound proteins are then analyzed with mass spectrometry. The profiles of mass spectra can be used for diagnosis or for identifying potential biomarkers. In this study, we analyzed the differential serum proteome profiles from MDS patients with an interstitial deletion of the long arm of chromosome 5 ((del(5q)) and control individuals. The aim was to identify disease-and therapyassociated markers for del(5q) MDS.
Materials and methods

MDS patients and treatment protocol
The present study involving MDS patients and control individuals undergoing ophthalmic surgery with no history of haematological disease was approved by the ethics committee of the participating institutions. All patients and control individuals received adequate information about the study and gave full consent. Two sets of samples were prepared for the identification of disease-and therapy-associated proteome changes. The first set included samples from 29 del(5q) MDS patients collected before treatments and 51 control samples. The second set consisted of paired samples from patients obtained before and after treatments with lenalidomide (Revlimid) (Celegene Corporation, Summit, NJ, USA). All samples were collected at St Johannes Hospital, Duisburg, Germany and Ninewells Hospital, Dundee, UK. The control group consisted of 17 male and 34 female individuals. The detailed demographic and clinical characteristics of the 29 MDS patients are shown in Table 1 . Of the 29 patients, 9 were male and 20 were female. The median age was 65 (41-83). A total of 21 patients had a single del(5q) abnormality and 8 had additional chromosomal abnormalities in addition to del(5q). The treatment protocol for the patients has been published. 13 Briefly each patient was initially given 10 mg of lenalidomide daily for 21 days of every 28-day cycle. The protocol was subsequently amended to give a 10 mg dose daily. For those patients whose treatment was interrupted by adverse effects and then resumed, a dose of 5 mg was given per day or every other day. Responses were assessed according to International Working Group criteria, 14 
Preparation of crude serum samples and serum fractions
Crude serum samples were prepared from 29 MDS patients before and/or after the treatment with lenalidomide at different time points, and from control individuals undergoing eye surgery. Briefly blood was drawn into standard hospital blood collection tubes and allowed to clot at room temperature for 30 min. The serum was separated by centrifugation at 3500 r.p.m. for 15 min and aliquotted in small volume (10À40 ml). Serum fractions were prepared with either a ProteinChip serum fractionation kit (K10-00007) (Ciphergen Biosystems, Fremont, CA, USA) or ProteinChip spin Q columns (C54-00017) (Bio-Rad Laboratories, Hemel Hempstead, UK) according to the manufacturer's instructions. All the crude serum samples and serum fractions were stored at À80 1C until ProteinChip array analysis.
ProteinChip array analysis
We did preliminary experiments to assess the performance of four different arrays, that is, IMAC30-Cu 2 þ , Q10, CM10 and H50 (Ciphergen Biosystems) in profiling MDS serum samples. A pooled MDS sample (mixture of an equal volume of serum sample from individual patients) and a pooled control sample (mixture of an equal volume of serum sample from individual control subjects) were analyzed in six replicates according to the manufacturer's instructions. As a result, two types of ProteinChip arrays, that is, IMAC30-Cu 2 þ , which mimics immobilized metal affinity chromatography and Q10 with a strong anion exchange chromatographic surface were used to obtain serum protein profiles. Serum samples, in small volume, were thawed on ice The arrays were equilibrated twice with 150 ml of binding buffer. Serum samples (100 ml per spot) were added onto the spots and incubated for 60 min at room temperature under vigorous shaking on a MicroMix 5 shaker (EURO/DPC, Gwynedd, UK). After incubation, the remaining samples were removed and the arrays were washed three times with 150 ml of binding buffer for 5 min, followed by two washes with high-performance liquid chromatography H 2 O. They were air-dried for 15 min and 0.6 ml of saturated sinapinic acid (Ciphergen Biosystems/Bio-Rad Laboratories) solution ( 
Data analysis and statistics
All data were obtained from duplicate experiments with either IMAC30-Cu 2 þ or Q10 profiling. Mass spectra obtained from individual experiments were processed with ProteinChip software 3.2 (Ciphergen Biosystems). Briefly, all spectra in an experiment were sorted according to their assigned groups and the mass accuracy was calibrated. Spectra were normalized using the total ion current in the low (m/z 2000-30 000) and high (m/z 30 000-1 60 000) mass range. Those spectra with a normalization factor below 0.5 or higher than 2 were excluded from the analysis. Peaks were detected automatically with the setting at two times the noise for both valley depth and peak height. Peak clustering among sample groups was performed with the Biomarker Wizard software (Ciphergen Biosystems) using the following settings: signal to noise ratio in the first pass, 5; minimum peak threshold, 5%; clustering mass window, 0.3%; signal to noise ratio in the second pass, 2. Those peaks detected within 0.15% mass to charge (m/z) units of each other across the spectra were considered as one cluster. Differential mass peak features between groups (Po0.05, Mann-Whitney U-test) were identified using the 'Sample Statistics' function of Biomarker Wizard software. Those peaks consistently showing a difference in duplicate experiments were selected and two intensity values of each peak were averaged. The resulting data were reanalyzed and those peaks still showing a difference (Po0.05, Mann-Whitney U-test or Wilcoxon-matched pairs test) were identified. Using 'Biomarker Patterns Software' (Ciphergen Biosystems) based on the 'Classification and Regression Tree' algorithm, we developed a classification model potentially useful for adding in the disease diagnosis. This model was based on the differential peak features detected by IMAC30-Cu 2 þ profiling with a peak at m/z 2791 as a main splitter. A second model was developed to distinguish between the responders and the non-responders using a peak feature at m/z 8559 detected by Q10 array profiling.
Assessments on the reproducibility of the array analyses
To assess the intra-and inter-assay variability, six replicates of a quality control serum sample prepared from a pool of 30 normal sera were included in each experiment. They were profiled with IMAC30-Cu 2 þ and Q10 arrays, and the spectral data were collected and analyzed as described in the previous sections.
Protein purification and identification
A range of differential peaks with the most significant changes and relatively strong intensity (45 and 41 in the low and high mass range, respectively) was selected for further characterization. These included peaks at m/z 2791, m/z 3274, m/z 3956, m/z 3972, m/z 4282, m/z 4298, m/z 7765, m/z 13737, m/z 13810, m/z 15089, m/z 15826 and m/z 79186. Serum samples were fractionated by strong anion exchange chromatography using spin columns, and proteins/peptides were enriched by ultrafiltration through membranes with different molecular weight cut-off. Those with a high (45 kDa) and a low (o5 kDa) molecular weights were further enriched by gel electrophoresis and reverse-phase chromatography, respectively. Enriched proteins were analyzed and identified by mass spectrometry and database interrogation (for more details see Supplementary Information).
Immunodepletion
Immunodepletion assays were carried out for the identification of platelet factor-4 (PF-4), transthyretin, haemoglobin, and transferrin using antibody-coupled Protein G-Sepharose beads (Sigma-Aldrich Company , Dorset, England). For each coupling, 50 ml of Protein G-Sepharose beads were washed with 3 ml of cold PBS and the beads were pelleted and resuspended in 0.5 ml of PBS containing 20 mg of an individual antibody. The beadsantibody solution was mixed at 4 1C, overnight on a rotator and then centrifuged briefly. The antibody-coupled beads were washed with cold PBS and then incubated with 100 ml of diluted serum sample (1:20 in PBS) for 2 h at 4 1C The mixture was centrifuged and the supernatant was collected as depleted serum. The beads were washed again with PBS (3 ml) and the bound proteins were eluted with 20 ml of 0.1 M glycine-HCl, pH 2.7. The eluate was collected and immediately mixed with 80 ml of PBS. In each assay, control incubations were carried out with goat IgG and uncoupled beads to confirm the specificity.
Measurements of serum levels of transferrin and PF-4 by enzyme-linked immunoabsorbent assay (ELISA)
Serum levels of transferrin and PF-4 were measured with the Human Transferrin ELISA Quantification kit (Bethyl Laboratories, Montgonery, TX, USA) and PF-4 ELISA kit (R&D Systems Europe, Abingdon, UK), respectively according to the manufacturer's instructions.
Results
The performance of various arrays in profiling MDS serum samples and the reproducibility of array analyses
In preliminary experiments, IMAC30-Cu 2 þ array profiling produced best mass spectra in terms of more peaks detectable and better peak resolution. Quantitative data from four experiments showed that IMAC30-Cu 2 þ and Q10 array profiling detected more peaks and also identified more differences compared with other array profiling. IMAC30-Cu 2 þ and Q10 arrays were subsequently used in the present study. To assess the intra-and inter-assay variability of the array analyses, we calculated the coefficient of variance of the intensities of the peak features commonly observed in all the spectra. When profiling with IMAC30-Cu 2 þ arrays, the average intra-assay coefficient of variance in the low and high mass range were 11.5% and 15.6%, respectively, in experiment 1 and 11.7% and 15.7%, respectively, in experiment 2. When profiling with Q10 arrays, the average intra-assay coefficient of variance in the low and high mass range were 8.7% and 19.2%, respectively, in experiment 1 and 9.4% and 12.5%, respectively, in experiment 2. These results indicated the low intra-assay variability. The two experiments were highly reproducible in the intensity of the commonly observed peak features, as the correlation coefficients for the two measurements were more than 0.99 when profiling with both IMAC30-Cu 2 þ and Q10 arrays.
Disease-associated serum proteome changes and proteome profiles associated with different clinical characteristics
When profiling with IMAC30-Cu 2 þ arrays, an average of 84 peak clusters were observed. Of these peaks, 41 showed a significant difference in intensity between the groups. Q10 array profiling detected an average of 72 peak clusters, 20 of which were significantly different between the groups. Supplementary Table 1 shows the quantitative information of the 61 significantly changed peak features that represent potential diseaseassociated markers. We developed a range of classification models using these peaks either individually or in different combinations. The best model was obtained with a peak at m/z 2791 as a main splitter (Figure 1a) . According to this model, the classification has a sensitivity of 93.1%, a specificity of 92.2% and an accuracy of 92.5%. In addition to disease-associated serum proteome changes, we attempted to identify serum proteome profiles associated with different clinical characteristics. Patients were grouped on the basis of a range of parameters, such as percent erythroblasts (o10% versus X10%), percent blasts (o5% versus X5%), karyotypes (del(5q) alone versus del(5q) plus additional abnormalities) and relapse from complete remission versus no relapse. The spectra data from paired groups were analyzed. We detected six differential peak features when profiling samples from the patients with o5% blasts (early disease forms, that is, refractory anemia and refractory anemia with ringed sideroblasts) and those from the patients with X5% blasts (advanced disease forms, that is, refractory anemia with excess blasts (RAEB)-I and II). Of these, five (m/z 2791, m/z 3956, m/z 8561, m/z 16986 and m/z 17086) showed stronger intensity in the group with o5% blasts, whereas one (m/z 8264) showed stronger intensity in the group with X5% blasts. A classification model constructed with two of the differential peaks, that is, m/z 8264 and m/z 16986 could distinguish the patients with X5% blasts from those with o5% blasts with a sensitivity of 90.9%, a specificity of 83.3% and an accuracy of 86.2% in cross-validation. In addition, a peak difference was observed between samples from patients with different percentage of erythroblast. The intensity of the peak (m/ z 9920) was more than two-fold stronger in the group with o10% erythroblasts. No differences were detected between other paired samples.
Having identified potential disease-associated peak features, we attempted to obtain their identities for further characterization. The first protein we characterized has a molecular weight of 79186 Da. Its quantitative information is shown in Figure 2 . The expression of this protein was decreased in the diseased samples (Figures 2a and c) , and was increased in the posttreatment samples from the responders (Figures 2b and d) . The protein was then enriched and identified by tandem mass spectrometry as serum transferrin precursor (Figure 3a-c) and the identification was confirmed by an immunodepletion assay (Figure 3d ). The data obtained by ProteinChip array analysis were validated by ELISA. The mean concentration in diseased Figure 1 Classification models potentially useful for adding in the disease diagnosis (a) and predicting the response to therapy (b). (a) Eighty subjects in the parent node (node1) are separated on the basis of the intensity of m/z 2791. Cases in the left child node (terminal node 1) are classified as control and those in the right child node (terminal node 2) are classified as diseased. (b) Eighteen subjects in the parent node (node1) are split according to a role, that is, a case in the parent node goes to the left child node (terminal node 1) if the intensity of its m/z 8559 is less than or equal to 8.341, otherwise it goes to the right one (terminal node 2). As a result, cases in the left and right node, respectively, are grouped as nonresponders and responders.
samples was 33% lower compared with the control (332.03± 60.08 mg per 100 ml in the control versus 221.59 ± 52.35 mg per 100 ml in the diseased, Po0.0001). After treatment, the concentration was increased in responders (268.85 ± 49.28 mg per 100 ml in pre-treatment versus 307.03±50.45 mg per 100 ml in post-treatment, P ¼ 0.023) and was not changed in non-responders (243.34 ± 38.39 mg per 100 ml in pre-treatment versus 225.92 ± 52.39 mg per 100 ml in post-treatment, P ¼ 0.4837).
A number of protein peaks in the low mass range were found increased in the diseased samples by IMAC30 profiling. The most significantly changed peak has an m/z value of 2791 and its intensity was increased more than five-fold. Information and Supplementary Table 2) .
Several peak features whose changes detected by Q10 array profiling were identified. A peak at m/z 13810 was decreased ca 48%, whereas the one at m/z 13737 was increased ca 1.4-fold in the diseased samples compared with the control (Figures 4c  and d and Supplementary Table 1 ). These two peaks were identified as variants of transthyretin by a combination of electrospray ionization tandem mass spectrometry and immunodepletion ( Supplementary Information and Supplementary  Figure 1a) . Two protein peaks at m/z 15089 and 15826 were significantly increased in diseased samples when profiling with Q10 ProteinChip arrays. Quantitatively the peaks at m/z 15826 and 15089 were increased ca 3.1-and 2.7-fold, respectively (Figures 4c and d and Supplementary Table 1 ). These two peaks were identified as haemoglobin a-and b-chain, respectively ( Supplementary Information and Supplementary Figure 1b) .
Identification of therapy-associated serum proteome changes
As shown in Table 2 , we identified 19 altered protein peak features as a result of therapy. Five of these alterations, that is, those at m/z 7564, m/z 7970, m/z 8134, m/z 9287 and m/z 10261 were commonly observed in both the responders and the non-responders, whereas others were detected in only one of the groups. From the differentially expressed proteins, we selected m/z 7765 for further characterization. This protein peak was different in intensity between the control and diseased, and between the pre-and post-treatment samples from the nonresponders ( Figure 5 , Table 2 and Supplementary Table 1) . Specifically its mean intensity was decreased ca 29% in diseased samples compared with the control and decreased ca 44% in the post-treatment samples from seven non-responders (Figures 5a and b) . We identified this protein as PF-4 ( Supplementary Information and Supplementary Figure 1c) . To validate the data obtained by ProteinChip array analysis, we measured the serum level of PF-4 by ELISA. The concentration of PF-4 in the diseased samples was ca 11% lower compared with the control (1848.28 ± 806.00 ng/ml in the diseased versus Proteomic analysis of serum proteome of myelodysplastic syndromes C Chen et al 2079.73 ± 443.73 ng/ml in the control, P ¼ 0.026) and that in the post-treatment samples from the non-responders ca 47% lower compared with the pre-treatment group (1372.36 ± 715.75 ng/ ml in the pre-treatment samples versus 723.79±252.81 ng/ml in the post-treatment samples, P ¼ 0.028) (Figures 5c and d) . There was a slight discrepancy between the data obtained by ProteinChip array analysis and ELISA concerning the PF-4 concentration in the post-treatment samples from the responders. We observed no difference in the intensity of m/z 7765 between the pre-and the post-treatment samples by array profiling, but detected a ca 27% decrease in concentration of PF-4 in the post-treatment samples from the responder group by ELISA (1810.09±515.02 ng/ml in the pre-treatment samples versus 1318.99 ± 296.30 ng/ml in the post-treatment samples, P ¼ 0.009, see Supplementary Figure 2a ). This may be explained by the mass spectrometry-based assays being semi-quantitative and thus, may not be as sensitive as ELISA. The result highlights the necessity of using confirmatory assays to validate the data obtained by ProteinChip array analysis. Another interesting finding from the ELISA experiments was that the concentrations of PF-4 were different between the responders and the nonresponders in the post-treatment, but not in the pre-treatment samples (Supplementary Figure 2b) , which could be a reflection of patients' differential responses to the treatments. To get more insights into the dynamic changes of PF-4 following treatments, we measured the concentrations of PF-4 in the serial samples collected before and after treatments. The dynamic changes of the serum level of PF-4 over time are shown in Supplementary  Figures 2c and d .
Differential serum proteome profiles between the responders and the non-responders
We analyzed 11 pre-treatment samples from the responders and seven from the non-responders. As summarized in Table 3 , in total eight peak features were different between the groups. To determine the usefulness of these differential peaks in distinguishing the responders from the non-responders, we employed them either individually or in combination to generate classification models and obtained the best one using one peak feature at m/z 8559 identified by Q10 array profiling (Figure 1b) . When this model was tested by 10-fold cross-validation, the sensitivity and specificity were 90.9% and 71.4%, respectively, and the accuracy was 83.3%.
Discussion
In the past few years, ProteinChip technology based on surfaceenhanced laser desorption/ionization time-of-flight mass spectrometry has been increasingly employed in the clinical research due to its exceptionally high throughput compared with other proteomic approaches, such as gel electrophoresis. There is evidence suggesting that it could be a powerful tool for characterizing the proteome of different tissues and identifying potential biomarkers for various diseases, including cancer. [15] [16] [17] [18] At the same time, great concerns have also been raised regarding its reproducibility and other instrumental and technical limitations. 19, 20 In the present study, we sought to determine whether serum protein expression profiling with surface-enhanced laser desorption/ionization time-of-flight mass spectrometry platform could be used to search for potential disease-and therapy-associated markers for MDS. We analyzed serum samples from patients with del(5q) MDS before and after treatment, and those from control individuals using IMAC30-Cu 2 þ and Q10 arrays. The data from quality control samples indicate that the intra-assay variation was low and our experiments were highly reproducible. To further validate results and exclude the possibility that observed peak differences were due to experimental/system variations, differences between serum samples were only considered real if they were identified in duplicate experiments. This strategy significantly increased the reliability of the assays.
We were able to detect a number of peak features whose intensity was altered in the diseased subjects. One of the most significantly changed peaks has an m/z value of 2791. Although we were unsuccessful in obtaining its protein identity, it is interesting that, a peak feature with the same m/z value was significantly increased in the plasma of breast cancer patients undergoing chemotherapy. 21 It was suggested that this peak might be associated with the apoptotic response of tumour cells induced by chemotherapy with paclitaxel. In our study the intensity of this peak was significantly increased in the diseased samples, a probable reflection of the increase of abnormal haemopoietic cells undergoing apoptosis in MDS. In addition to m/z 2791, a group of peaks at m/z 3274, m/z 3956, m/z 3972, m/z 4282 and m/z 4298 derived from inter-a-trypsin inhibitor heavy chain H4 were also significantly increased in the diseased samples. Quantitative alteration of the fragments of inter-a trypsin inhibitor, heavy chain H4 was previously found to be associated with various cancer diseases, [22] [23] [24] indicating that the alteration of these species is not specific to MDS. Inter-a trypsin inhibitor, heavy chain H4 has been shown to be a positive acute phase protein in human and other animals, [25] [26] [27] thus the increase of these species might be associated with the inflammatory processes ongoing in MDS. 28 We also detected Proteomic analysis of serum proteome of myelodysplastic syndromes C Chen et al changes in transferrin, variants of transthyretin and haemoglobin a-and b-chains in diseased samples. All these proteins have been identified by others as disease-associated markers. [29] [30] [31] [32] [33] [34] [35] [36] We obtained a classification model that could distinguish between the diseased and the control subjects with high sensitivity and specificity. Because of the restriction of sample size, we assessed the performance of this model using a procedure of 10-fold cross validation. We are aware of the limitations of this technique and would suggest testing this model with more independent samples. Proteomic profiling of serum samples from patients with MDS using ProteinChip technology was previously carried out by Aivado et al.
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Although the overall aim to identify disease-associated serum proteome changes was the same, there were major differences between this and our study in samples and methodology. First, our study focused specifically on a group of patients with del(5q), whereas the previous study included patients with all MDS subtypes. Second, Aivado et al. included patients with non-MDS cytopenias as controls in addition to healthy subjects, and were able to validate the profiles using two sets of independent serum samples. Our study has limitations in these respects. Third, different ProteinChip arrays were used to profile the serum samples in the two studies. We analyzed the crude serum samples with IMAC30-Cu 2 þ and Q10 arrays, whereas Aivado et al. employed H50 and CM10 arrays to profile fractionated samples. As a result, the disease-associated proteome changes identified in our study are completely different from those identified by Aivado et al. Given the above mentioned differences, our study is novel and complementary to the one by Aivado et al.
We analyzed serum samples from patients with del(5q) MDS before and after treatment and detected a number of peak features the intensity of which was altered in the post-treatment samples. One of the peaks at m/z 7765 was identified as PF-4 by an immunodepletion assay. PF-4 is a chemokine released from the a-granules of activated platelet and it has been identified as potential toxicity-or disease-associated markers. [37] [38] [39] This protein showed a 29% decrease in peak intensity and an 11% decrease in concentration in diseased samples. Another interesting finding of our study was that PF-4 concentrations were not different between the responders and the non-responders before lenalidomide treatment, but were significantly different after treatment. The concentration in non-responders was significantly lower than that in responders. This could be a reflection of differential effects of lenalidomide on the responders and the non-responders. The dynamic changes of PF-4 concentrations in the serial samples collected before and after treatment from the responders and the non-responders might be relevant to the clinic side effects caused by the treatment, that is, severe neutropenia and thrombocytopenia in the early stages of the treatment. The decrease of PF-4 might be due to the inhibition of del(5q) progenitor cells by lenalidomide and the subsequent reduction of megakaryocytes that were main producers of PF-4, as it has been shown that lenalidomide inhibited the growth of del(5q) haemopoietic progenitors in vitro. 40 The later increase of PF-4 observed in some of the responders could be an indication that the treatment resulted in the reconstitution of the normal haemopoiesis in these patients. We demonstrated that the responders and the non-responders had different serum proteome profiles that could potentially be used to predict response to treatment with lenalidomide. The predictive power had a reasonable sensitivity and a slightly low specificity. Such an approach using protein patterns to predict patients as responders and non-responders to a therapy deserves additional study and should be confirmed with a larger sample size that is possible using automated SELDI-TOF-MS procedures. In conclusion, we identified inter-a trypsin inhibitor, heavy chain H4 (fragments), serum transferrin, transthyretin (variants), haemoglobin and a protein peak at m/z 2791 as potential disease-associated markers for del(5q) MDS. We analysed for the first time the proteome of serum samples obtained from patients treated with lenalidomide and identified PF-4 and a peak at m/z 8559 as potential therapy-associated markers that may be useful for monitoring and predicting the responses to therapy.
